IN8bio Launches $2.8M At-The-Market Offering to Raise Capital
INAB sits 56% above its 52-week low of $1.17.
Summary
IN8bio has launched a new At-The-Market (ATM) equity offering program with JonesTrading, aiming to sell up to $2.8 million in common stock. This move, which replaces a prior agreement, comes as the company faces a confirmed 'going concern' warning and a cash runway extending only through April 2027. The $2.8 million offering represents over 15% of the current market capitalization, indicating significant potential dilution for shareholders. This capital raise is critical for the company's short-term survival given its increased cash burn and paused R&D programs.
At the time of this announcement, INAB was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.4M. The 52-week trading range was $1.17 to $5.61. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.